Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …

A proper clinical evaluation of patients with Multiple Sclerosis (MS) is of great importance to
detect MS progression. It provides important data for physicians on their daily practice as …

Modern management of MS targets No Evidence of Disease Activity (NEDA): no clinical
relapses, no magnetic resonance imaging (MRI) disease activity and no disability …

Secondary progressive multiple sclerosis (SPMS) is the second most common form of
multiple sclerosis (MS). One in two relapse remitting multiple sclerosis (RRMS) patients will …

PURPOSE OF REVIEW Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders
(NMOSDs) are chronic autoimmune demyelinating conditions of the central nervous system …

Development of disease-modifying therapies including monoclonal antibody (mAb)-based
therapeutics for the treatment of multiple sclerosis (MS) has been extremely successful over …

Objective: To understand how longitudinal serum neurofilament light chain (sNfL) patterns
can inform its use as a prognostic biomarker in multiple sclerosis (MS) and evaluate whether …

Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are
autoimmune central nervous system conditions with increasing incidence and prevalence …

Background: Whole brain atrophy (WBA) estimates in multiple sclerosis (MS) correlate more
robustly with clinical disability than traditional, lesion-based metrics. We compare Structural …

Purpose: To study which brain volume measures best differentiate early relapsing MS (RMS)
and secondary progressive MS (SPMS) patients and correlate with disability and cognition …